Recent Company News

• 07:03 AM ET Aug 21, 2025
  

  PureTech Health showcases Differentiated IPF Strategy (133.0000p, -0.4)

• 12:26 PM ET Aug 13, 2025
  

  PureTech Health founded entity Vedanta Biosciences announces Phase 2 study of VE202 in ulcerative colitis did not meet primary endpoint (133.8000p, 0)

• 07:03 AM ET Aug 12, 2025
  

  PureTech Health announces the launch of a new founded entity Celea Therapeutics (128.0000p, -1.6)

• 07:21 AM ET Jul 29, 2025
  

  StreetAccount Summary - European unusual volume traders

• 07:18 AM ET Jul 17, 2025
  

  PureTech Health founded entity Seaport Therapeutics announces first patient dosed in Phase 2b BUOY-1 study of SPT-300 in MDD, with or without anxious distress (136.0000p, -1)

• 02:06 AM ET Jul 16, 2025
  

  PureTech Health CEO Bharatt Chowrira, steps away (133.4000p, 0)

• 12:47 PM ET Jul 08, 2025
  

  PureTech announces Chair Raju Kucherlapati has stepped down (127.8000p, 0)

• 02:10 AM ET Jun 26, 2025
  

  PureTech Health notes Vor Bio announcement of exclusive global license agreement with RemeGen for late-stage autoimmune asset and $175M private placement (124.4000p, 0)

• 05:32 PM ET May 20, 2025
  

  PureTech Health provides further insights into Phase IIb ELEVATE IPF trial of deupirfenidone (LYT-100) at ATS 2025 (129.4000p, 0)

• 07:03 AM ET May 01, 2025
  

  PureTech Health to present results from Phase 2B ELEVATE IPF trial of LYT-100 at the ATS International Conf (127.0000p, +4)